By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288


SEARCH JOBS
AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.


Key Statistics


Email: n/a
Ownership: Public

Web Site: AmpliPhi Biosciences Corporation
Employees:
Symbol: APHB
 





Collaborations

Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.





Company News
AmpliPhi Biosciences Corporation (APHB) To Present Research On Efficacy Of A Novel Bacteriophage Cocktail In S. Aureus Lung Infection Model At ICAAC/ICC 2015 8/3/2015 11:00:18 AM
AmpliPhi Biosciences Corporation (APHB) To Present Research On Efficacy Of A Novel Bacteriophage Cocktail In S. Aureus Lung Infection Model At ICAAC/ICC 2015 7/31/2015 8:09:58 AM
AmpliPhi Biosciences Corporation (APHB) Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization 6/12/2015 9:27:21 AM
AmpliPhi Biosciences Corporation (APHB) Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization 6/12/2015 8:33:38 AM
AmpliPhi Biosciences Corporation (APHB) To Present New Data On Biological Activity Of Nebulized Anti-Pseudomonal Bacteriophage 6/8/2015 11:18:02 AM
AmpliPhi Biosciences Corporation (APHB)’s Bacteriophage Manufacturing Facility Receives cGMP Certification 6/3/2015 7:49:35 AM
AmpliPhi Biosciences Corporation (APHB) Provides Corporate Update And Reports First Quarter 2015 Financial Results 5/19/2015 12:48:32 PM
AmpliPhi Biosciences Corporation (APHB) Provides Corporate Update And Reports First Quarter 2015 Financial Results 5/19/2015 10:04:09 AM
AmpliPhi Biosciences Corporation (APHB) Announces M. Scott Salka As New CEO 5/1/2015 10:21:36 AM
AmpliPhi Biosciences Corporation (APHB) Granted European Patent For Bacteriophage Therapy To Fight Biofilm-related Bacterial Infections 3/31/2015 8:52:38 AM
12345678910...
//-->